# Gut microbial composition and human psychiatric symptoms: research update

Dated 5 October 2026. Local prepublication addendum; archived grade unchanged.

Human associations, animal transfer experiments and clinical microbiome interventions address different causal steps. Recent adjunctive FMT findings strengthen an intervention line in depression, while human mediator specificity and generalization across psychiatric disorders remain unresolved.

## Research timeline

Electronic year is used where recorded; issue year is retained in each source card. The chronology is selected, not exhaustive, and does not establish priority or causation.

| Year | Primary study | Design and finding | Inference limit |
|---|---|---|---|
| 2016 | [Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism.](https://pubmed.ncbi.nlm.nih.gov/27067014/) | Human-donor transfer to germ-free mice. Depression-donor microbiota produced depressive-like behaviour and metabolic changes. | Germ-free host conditions and cross-species transfer bound applicability. |
| 2016 | [Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat.](https://pubmed.ncbi.nlm.nih.gov/27491067/) | Human-donor transfer to microbiota-depleted rats. Depression-associated donor microbiota induced behavioural and physiological changes in recipients. | Rat phenotypes and donor confounding do not prove human disease sufficiency. |
| 2017 | [A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression.](https://pubmed.ncbi.nlm.nih.gov/28068788/) | Probiotic randomized low-mood trial. The tested formulation did not provide evidence of a symptom benefit. | A null formulation/population result does not exclude every microbiome intervention. |
| 2017 | [Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.](https://pubmed.ncbi.nlm.nih.gov/28483500/) | Probiotic placebo-controlled IBS pilot. Depression scores and brain-activation measures improved with the tested strain. | IBS population and strain-specific intervention do not establish a general psychiatric mechanism. |
| 2022 | [Gut microbiome-wide association study of depressive symptoms.](https://pubmed.ncbi.nlm.nih.gov/36473852/) | Two-cohort microbiome association. Several taxa were associated with depressive symptoms across cohorts. | Association and inferred neuroactive potential do not establish effector delivery to the brain. |
| 2023 | [Gut microbiota changes require vagus nerve integrity to promote depressive-like behaviors in mice.](https://pubmed.ncbi.nlm.nih.gov/37131071/) | Mouse transfer plus vagotomy. Vagotomy prevented the tested microbiota-induced behavioural and neurogenic effects. | Mouse route necessity is not established human vagal mediation. |
| 2025 | [Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/39504580/) | Bipolar/schizophrenia probiotic randomized trial. Gut-health outcomes improved; a broad psychiatric benefit was not established. | Gastrointestinal or exploratory memory effects are not disorder-wide symptom efficacy. |
| 2026 | [Adjunctive fecal microbiota transplantation for major depressive disorder: A randomized, double-blind, placebo-controlled trial.](https://pubmed.ncbi.nlm.nih.gov/42309058/) | Adjunctive depression FMT randomized trial. The report linked improved adjunctive outcomes with engraftment, bile acids and mediation analysis. | Statistical mediation does not directly randomize the proposed bile-acid mechanism. |

## Research gaps

### G1: Which microbial function carries a human depression-treatment effect?

Evidence anchors: [P36473852](https://pubmed.ncbi.nlm.nih.gov/36473852/), [P42309058](https://pubmed.ncbi.nlm.nih.gov/42309058/), [P27491067](https://pubmed.ncbi.nlm.nih.gov/27491067/).

Competing explanation: Taxa can be markers of diet, medication, inflammation or a broader microbial functional state.

Discriminating test and controls: Replicated, strain/function-resolved randomized interventions with repeated metabolites, symptoms and prospective mediator analysis; stabilize medication and diet.

### G2: Is the vagus a necessary human route?

Evidence anchors: [P37131071](https://pubmed.ncbi.nlm.nih.gov/37131071/), [P28483500](https://pubmed.ncbi.nlm.nih.gov/28483500/), [P42309058](https://pubmed.ncbi.nlm.nih.gov/42309058/).

Competing explanation: Immune or circulating metabolite routes may contribute alongside vagal signals.

Discriminating test and controls: Human autonomic and mediator measurements within controlled interventions, complemented by model blockade/rescue; do not equate autonomic correlation with necessity.

### G3: When do positive and null clinical effects occur?

Evidence anchors: [P28483500](https://pubmed.ncbi.nlm.nih.gov/28483500/), [P28068788](https://pubmed.ncbi.nlm.nih.gov/28068788/), [P39504580](https://pubmed.ncbi.nlm.nih.gov/39504580/), [P42309058](https://pubmed.ncbi.nlm.nih.gov/42309058/).

Competing explanation: Formulation, diagnosis, baseline microbiota, concurrent treatment or gastrointestinal improvement may modify effects.

Discriminating test and controls: Independent multisite replication with prespecified diagnosis/strain strata, matching expectancy and gastrointestinal symptoms, and a clear primary psychiatric outcome.

### G4: Does benefit persist after dosing and engraftment changes?

Evidence anchors: [P42309058](https://pubmed.ncbi.nlm.nih.gov/42309058/), [P28068788](https://pubmed.ncbi.nlm.nih.gov/28068788/), [P36473852](https://pubmed.ncbi.nlm.nih.gov/36473852/).

Competing explanation: Short-lived symptom improvement may reflect concurrent antidepressant response or nonspecific treatment effects.

Discriminating test and controls: Blinded longer follow-up with repeated microbial function and clinical relapse measures; record adherence, additional care and donor/product identity.

## Methods and access

Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.

This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.

Checked timeline sources: 8; selected full-text checks: 1; abstract-excerpt checks: 7; metadata-only historical anchors: 0. Complete papers examined in this update: 0.

Historical scorecards declare schema 5.4. This enrichment uses HSEF v5.3 causal distinctions without retrospectively relabelling or rescoring those files.

Targeted paper-check scope: Results Par32: vagotomy or sham surgery preceded transfer by two weeks; vagotomy prevented the tested behavioural/neurogenesis deficits in mice.